KCTD3

Across TCGA pan-cancer cohorts, KCTD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated KCTD3 data layer compared with 21 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher KCTD3 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated KCTD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

LUAD, UCEC, and SCLC are the cancer types where KCTD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	II,III,IV	0.053	0.751	<.001	30	view →
UCEC	DFS	Median	All	0.969	0.615	.005	28	view →
SCLC	DFS	Median	All	1.000	0.269	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

KCTD3–LUAD (OS)

Open the LUAD breakdown →